GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Accolade Inc (STU:4NE1) » Definitions » Research & Development

Accolade (STU:4NE1) Research & Development : €88.8 Mil (TTM As of Aug. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Accolade Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Accolade's Research & Development for the three months ended in Aug. 2024 was €20.4 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Aug. 2024 was €88.8 Mil.

Accolade Research & Development Historical Data

The historical data trend for Accolade's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Accolade Research & Development Chart

Accolade Annual Data
Trend Feb18 Feb19 Feb20 Feb21 Feb22 Feb23 Feb24
Research & Development
Get a 7-Day Free Trial 38.80 41.31 73.71 94.66 91.92

Accolade Quarterly Data
Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 23.48 21.68 22.42 24.34 20.39

Accolade Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Aug. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €88.8 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Accolade  (STU:4NE1) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Accolade Research & Development Related Terms

Thank you for viewing the detailed overview of Accolade's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Accolade Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Accolade Inc (STU:4NE1) » Definitions » Research & Development
Comparable Companies
HCAT SLGC SHCR AMWL DH SLP PHR SPOK TALK TRHC VEEV GEHC TSE:2413 HQY ASX:PME RCM TXG DOCS PGNY EVH
Traded in Other Exchanges
ACCD:USA
Address
1201 Third Avenue, Suite 1700, Seattle, WA, USA, 98101
Website
https://www.accolade.com
Accolade Inc offers technology-enabled solutions that help people understand, navigate, and utilize the healthcare system and their workplace benefits. The company's platform combines open, cloud-based intelligent technology with multimodal support from a team of Accolade Care Advocates and clinicians, including registered nurses, physician medical directors, pharmacists, primary care physicians, and other professionals to provide advocacy, medical opinion, and virtual primary care services.

Accolade Headlines

No Headlines